Waltham, MA., January 19th, 2026 – BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as an advisor to BVI and begin a new role as senior advisor to TPG Capital.  Read More

• Milestone strengthens the company’s leadership in advanced IOL innovation
• FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients
• Proprietary design features anchor the launch of BVI’s expanded U.S. IOL portfolio

WALTHAM, Mass., Oct. 14, 2025 — BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone reinforces BVI’s leadership in premium IOLs and expands advanced vision solutions for U.S. patients. Read More

• BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS).  

Waltham, Mass., September 3, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures. Read More

• Vitreoretinal surgeons can now benefit from access to BVI's high-quality ISPAN^TM ophthalmic gases, supporting the critical needs of advanced retinal procedures.
• This latest development leverages BVI’s U.S. distribution network to ensure faster, more efficient delivery to surgeons and clinics.

WALTHAM, Mass., August 11, 2025 – BVI Medical, a leading global ophthalmic device company at the forefront of advancements in eye surgery, today announced its official launch of ISPAN^TM ophthalmic gases.  This is the first ever introduction by BVI of retinal gases for the US market. Read More

• The Council will serve as an advisory group, guiding BVI on corporate strategy, unmet clinical needs, product development, and surgical best practices.
• This initiative marks a key step in BVI’s global expansion, with plans underway for a European Surgical Advisory Board to further strengthen international partnerships

WALTHAM, Mass., August 6th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the formation of its first U.S. Surgical Leadership Council. This distinguished group of seven leaders spans the fields of cataract, retina, and glaucoma surgery—each dedicated to shaping the future of ophthalmology through collaboration and insight-driven innovation. Read More